We are live on ! Find out more
SABS icon

SAB Biotherapeutics
SABS

25 hedge funds and large institutions have $8.48M invested in SAB Biotherapeutics in 2024 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 2 increasing their positions, 4 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

200% more first-time investments, than exits

New positions opened: 6 | Existing positions closed: 2

14% more funds holding

Funds holding: 22 → 25 (+3)

0.16% more ownership

Funds ownership: 33.88% → 34.04% (+0.16%)

12% less capital invested

Capital invested by funds: $9.69M → $8.48M (-$1.21M)

50% less repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 4

Holders
25
Holders Change
+3
Holders Change %
+13.64%
% of All Funds
0.36%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
6
Increased
2
Reduced
4
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
HWM
HB Wealth Management
Georgia
+$301K
2
Kovitz Investment Group Partners
Kovitz Investment Group Partners
Illinois
+$53.2K
3
KAS
Kestra Advisory Services
Texas
+$33K
4
Citadel Advisors
Citadel Advisors
Florida
+$28.5K
5
BlackRock
BlackRock
New York
+$23.3K

Top Sellers

Rank Fund Capital Flow
1
RI
RTW Investments
New York
-$365K
2
Millennium Management
Millennium Management
New York
-$2.32K
3
TRCT
Tower Research Capital (TRC)
New York
-$853
4
Bank of America
Bank of America
North Carolina
-$188
5
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT)
United Kingdom
-$19
Name Holding Trade Value Shares
Change 		Change in
Stake
BI
1
BVF Inc
California
$2.48M – – –
RI
2
RTW Investments
New York
$1.72M -$365K -131,670 -17%
Marshall Wace
3
Marshall Wace
United Kingdom
$1.24M – – –
SC
4
Sessa Capital
New York
$1.24M – – –
Vanguard Group
5
Vanguard Group
Pennsylvania
$746K – – –
HWM
6
HB Wealth Management
Georgia
$293K +$301K +108,600 New
Geode Capital Management
7
Geode Capital Management
Massachusetts
$182K +$22.5K +8,127 +14%
Millennium Management
8
Millennium Management
New York
$140K -$2.32K -838 -2%
Pathstone Holdings
9
Pathstone Holdings
New Jersey
$137K – – –
First Manhattan
10
First Manhattan
New York
$66.4K – – –
BlackRock
11
BlackRock
New York
$59.8K +$23.3K +8,413 +61%
FPB
12
First PREMIER Bank
South Dakota
$52K – – –
Kovitz Investment Group Partners
13
Kovitz Investment Group Partners
Illinois
$51.8K +$53.2K +19,201 New
KAS
14
Kestra Advisory Services
Texas
$32.2K +$33K +11,930 New
Citadel Advisors
15
Citadel Advisors
Florida
$27.8K +$28.5K +10,305 New
Osaic Holdings
16
Osaic Holdings
Arizona
$12.2K – – –
TRCT
17
Tower Research Capital (TRC)
New York
$5.63K -$853 -308 -13%
Morgan Stanley
18
Morgan Stanley
New York
$1.89K – – –
PGAM
19
Princeton Global Asset Management
New Jersey
$1.35K – – –
GI
20
GS Investments
Minnesota
$540 – – –
JP Morgan Chase
21
JP Morgan Chase
New York
$286 – – –
S
22
Sachetta
Massachusetts
$270 +$277 +100 New
Bank of America
23
Bank of America
North Carolina
$262 -$188 -68 -41%
HI
24
Harbour Investments
Wisconsin
$135 – – –
Barclays
25
Barclays
United Kingdom
$27 +$28 +10 New
1
2

SABS Hedge Fund Activity: Q3 2024 in Review

25 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in SAB Biotherapeutics (SABS) for Q3 2024, worth a combined $8.48M — down 12% from $9.69M a quarter earlier.

Buyers outnumbered sellers: 6 funds opened new SABS positions and 2 closed out — a net gain of 4 holders — while 2 added to existing stakes and 4 trimmed.

The largest buyer was HB Wealth Management, opening a new position worth an estimated $301K. The largest seller was RTW Investments, cutting an estimated $365K.

  • 25 institutional investors held SAB Biotherapeutics (SABS) as of Q3 2024, up from 22 in Q2 2024.
  • Funds reported $8.48M of SAB Biotherapeutics stock for Q3 2024, down 12% quarter-over-quarter.
  • 6 funds opened new SAB Biotherapeutics positions in Q3 2024 and 2 closed out, a net change of +4 holders.
  • The largest SAB Biotherapeutics buyer in Q3 2024 was HB Wealth Management, an estimated $301K added.
  • The largest SAB Biotherapeutics seller in Q3 2024 was RTW Investments, an estimated $365K sold.

Based on aggregated 13F filings for Q3 2024.